...returned rights to its sole product-- a preclinical respiratory syncytial virus (RSV) vaccine-- to originator Mymetics Corp....
...Inc. (Tokyo:4503) NA (A) Infectious Single target 2013 2016 Returned rights to sole product to Mymetics Corp....
...Co. Inc. (NYSE:MRK), Kenilworth, N.J. Mitobridge Inc., Cambridge, Mass. MPM Capital, South San Francisco, Calif. Mymetics Corp....

...I Inovio Pharmaceuticals Inc. Pennvax-GP DNA vaccine targeting HIV clades A, C and D Preclin Mymetics Corp....

...emulsion MER4101, an influenza vaccine Mercia Pharma Inc. Preclinical P3CSK4 TLR2 lipopeptide ligand RSV vaccine Mymetics Corp....

...that is in preclinical development for respiratory syncytial virus (RSV). The vaccine was licensed from Mymetics Corp....

...RSV Corp. will develop a preclinical vaccine for respiratory syncytial virus (RSV) licensed from Mymetics. Mymetics...
...the company, ClearPath has the option of attracting new partners to continue development and commercialization. Mymetics Corp....

...Md.) will develop a preclinical vaccine for respiratory syncytial virus (RSV) licensed from Mymetics Corp. (OTCBB:MYMX). Mymetics...
...milestones, plus royalties. Astellas will fund development of the RSV vaccine through Phase IIb testing. Mymetics...

...new strategic directions," including the potential relocation of the company to the U.S. from Switzerland. Mymetics...
...its location in Switzerland and will continue to explore strategic options for its vaccine candidates. Mymetics Corp....

...Vaccine company Mymetics Corp. (OTCBB:MYMX) appointed CFO and COO Ronald Kempers as president and CEO. He replaces...
...new strategic directions," including the potential relocation of the company to the U.S. from Switzerland. Mymetics...
...its location in Switzerland and will continue to explore strategic options for its vaccine candidates. Mymetics...